Secret Sales Can Still Kill a Patent — Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc.
October 27, 2026 | Intellectual Property News, Legal NewsDecision: Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., 586 U.S. 123 (2019) — U.S. Supreme Court, decided January 22, 2019 (unanimous).
The holding. A sale of an invention can trigger the patent law’s on-sale bar even if the buyer is bound by confidentiality and the public never learns what the invention is. Helsinn, a Swiss drug maker, had licensed a nausea drug to a marketing partner under a confidentiality agreement more than a year before it filed for a patent on the drug’s dose. When a generic maker later challenged the patent, the Supreme Court held that the earlier deal counted as a sale under the America Invents Act (AIA). The AIA’s added phrase — that an invention must be “otherwise available to the public” — did not change the long-standing rule that a commercial sale need not disclose the invention to the public to start the one-year clock.
What it means. The on-sale bar is a trap that has nothing to do with whether competitors could have learned about your invention. What matters is whether you commercialized it — or offered to — more than a year before filing. A licensing deal, a distribution agreement, or a supply contract can all count, even when the technical details stay behind a confidentiality clause. For patent owners, the lesson is to calendar the filing deadline from the first commercial discussion, not from the first public disclosure. For accused infringers, it is worth digging into a patentee’s early business dealings: a confidential agreement signed years before the patent application may be the invalidity argument that wins the case.
Sources:
- Opinion: Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., 586 U.S. 123 (2019)
- Also consulted: Marshall, Gerstein & Borun LLP alert, “Supreme Court Confirms Secret Sales Can Invalidate Patents” (Jan. 24, 2019); Faegre Drinker, “Supreme Court Decides Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc.” (Jan. 22, 2019)